Beijing Sun Novo Pharmaceutical Research Co Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.065x

Beijing Sun Novo Pharmaceutical Research Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a cash flow conversion efficiency ratio of 0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥76.07 Million ≈ $11.13 Million USD) by net assets (CN¥1.17 Billion ≈ $170.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)

Cash flow conversion efficiency of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025. This chart illustrates how Beijing Sun Novo Pharmaceutical Research Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Beijing Sun Novo Pharmaceutical Research (688621) share price today for real-time trading data and today's change.

Beijing Sun Novo Pharmaceutical Research Co Ltd Cash Flow Conversion Ratio Explained

Beijing Sun Novo Pharmaceutical Research Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Beijing Sun Novo Pharmaceutical Research Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Beijing Sun Novo Pharmaceutical Research Co Ltd ranked by their cash flow conversion efficiency. Also see Beijing Sun Novo Pharmaceutical Research stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Hangzhou Sunrise Technology Co Ltd SHE:300360	0.057x
Blacksky Technology Inc NYSE:BKSY	-0.021x
I.E.S Holdings Ltd TA:IES	0.006x
Luye Pharma Group Ltd F:LUP	0.019x
Tongyang Life KO:082640	0.117x
Addnode Group AB (publ) ST:ANOD-B	0.022x
Bank Sinarmas Tbk JK:BSIM	0.273x
Southside Bancshares, Inc. NASDAQ:SBSI	0.048x

Annual Cash Flow Conversion Efficiency for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025. Review 688621 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥1.23 Billion ≈ $180.50 Million	CN¥93.21 Million ≈ $13.64 Million	0.076x	+160.23%
2024-12-31	CN¥1.10 Billion ≈ $161.35 Million	CN¥32.02 Million ≈ $4.69 Million	0.029x	-66.94%
2023-12-31	CN¥1.06 Billion ≈ $154.71 Million	CN¥92.86 Million ≈ $13.59 Million	0.088x	-23.27%
2022-12-31	CN¥908.23 Million ≈ $132.90 Million	CN¥103.96 Million ≈ $15.21 Million	0.114x	-0.18%
2021-12-31	CN¥769.64 Million ≈ $112.62 Million	CN¥88.25 Million ≈ $12.91 Million	0.115x	-64.88%
2020-12-31	CN¥192.92 Million ≈ $28.23 Million	CN¥62.99 Million ≈ $9.22 Million	0.327x	-31.94%
2019-12-31	CN¥118.76 Million ≈ $17.38 Million	CN¥56.97 Million ≈ $8.34 Million	0.480x	-19.71%
2018-12-31	CN¥73.82 Million ≈ $10.80 Million	CN¥44.11 Million ≈ $6.45 Million	0.597x	+147.99%
2017-12-31	CN¥33.25 Million ≈ $4.87 Million	CN¥8.01 Million ≈ $1.17 Million	0.241x	--

About Beijing Sun Novo Pharmaceutical Research Co Ltd

SHG:688621 China Drug Manufacturers - Specialty & Generic

Market Cap

$872.56 Million

CN¥5.96 Billion CNY

Market Cap Rank

#9180 Global

#2243 in China

Share Price

CN¥53.24

Change (1 day)

-4.04%

52-Week Range

CN¥47.96 - CN¥78.30

All Time High

CN¥128.22